Durect Corporation (DRRX)

Durect Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies to treat chronic debilitating diseases and enable biotechnology products. These platform technologies include the Saber Delivery System (a patented and versatile depot injectable useful for proteins, peptides and small molecule delivery), the Oradur sustained release oral gel-cap technology (an oral sustained release technology with several potential abuse deterrent properties), the Transdur transdermal patch technology, the Durin Biodegradable Implant (drug-loaded implant system) and the Microdur Biodegradable Microparticulates (microspheres injectable system). DRRX also partners with pharmaceutical and biotechnology companies to develop and commercialize proprietary and enhanced pharmaceutical products based on its technologies. DRRX has seven disclosed on-going development programs of which six are in collaboration with pharmaceutical partners. DRRX is also developing DUR-928, an endogenous orally bioavailable small molecule that modulates the activity of various nuclear receptors that play an important regulatory role in lipid homeostasis, inflammation and cell survival.

Published Reports

DRRX 4Q18 rev
DRRX Posimir update rev
DRRX corporate update rev
DRRX 3Q18 rev
DRRX 2Q18 rev
DRRX Perseris rev
DRRX-1Q18-rev.pdf
DRRX 4Q17 rev
DRRX-3Q17-rev-1.pdf
DRRX Posimir data rev
DRRX 2Q17 rev
DRRX 1Q17 rev
DRRX Sandoz partnership rev
DRRX EASL p1b rev
DRRX 3117 rev
drrx-3q16-rev
drrx-remoxy-crl-9-30-16-rev
DRRX management days rev
DRRX 1Q16 rev
DRRX 4Q15 rev
DRRX BostonNDR 9 30 15 rev
DRRX 3Q15 rev
DRRX initiation of Coverage.8.31.15